HRT vs BHRT: Understanding the Difference and the Hype

By Glow Health | Menopause & Sexual Health Specialists

If you've spent any time researching hormone therapy, you've probably encountered two sets of initials that seem to mean similar things but carry very different connotations: HRT and BHRT. You may have seen BHRT described as the "natural" alternative to conventional hormones, or heard that bioidentical hormones are safer or more effective. You may also have encountered the opposite view, that BHRT is an unregulated wellness trend with little science behind it.

The reality is more nuanced than either camp suggests, and the confusion between these terms causes real harm by leading women to either avoid hormone therapy they could genuinely benefit from, or to pursue compounded preparations under the impression they are meaningfully different from regulated options.

Here is what the evidence actually shows.

What HRT means

HRT stands for hormone replacement therapy. The technically correct term is menopausal hormone therapy (MHT), which is now preferred by most clinicians and organizations including The Menopause Society (TMS) because it more accurately describes what the treatment does. In practice, HRT remains the term most women use and search for, so you'll see both used interchangeably throughout this post and across menopause medicine more broadly.

HRT refers broadly to the use of hormones, most commonly estrogen and progesterone, to address symptoms of the menopausal transition. It encompasses a wide range of formulations, doses, and delivery methods, including pills, patches, gels, sprays, creams, and vaginal preparations. FDA-approved hormone therapy products are manufactured under rigorous quality control standards, with consistent dosing and safety data from clinical trials.

What BHRT means, and where it gets complicated

BHRT stands for bioidentical hormone replacement therapy. The term "bioidentical" refers to hormones that are chemically identical in structure to the hormones naturally produced by the human body. Estradiol, progesterone, and testosterone are all examples of bioidentical hormones.

Here is where the confusion begins: many FDA-approved hormone therapy products are already bioidentical. Estradiol patches, gels, sprays, pills, and vaginal rings all contain bioidentical estrogen. Oral micronized progesterone (brand name Prometrium) is bioidentical progesterone. These are regulated, rigorously tested medications with established safety profiles.

When most people use the term BHRT, however, they are referring specifically to compounded bioidentical hormones, which are custom-mixed preparations made by compounding pharmacies, typically based on hormone testing through saliva or urine. This is a meaningfully different category, and the distinction matters.

Compounded BHRT: what you need to know

Compounding pharmacies create custom hormone preparations that are not FDA-approved as finished products. They may combine multiple hormones in a single preparation, adjust doses based on individual testing, and offer delivery methods not available in commercial formulations.

Compounding fills genuine and important clinical gaps. Some women have allergies to inactive ingredients in standard products, require doses outside the range of available commercial options, or need testosterone, which has no FDA-approved preparation specifically for women in the United States. Many excellent compounding pharmacies test and validate their products rigorously, and working with a reputable compounder under the guidance of a knowledgeable clinician can be a legitimate and effective approach to hormonal care.

Where the picture gets more complicated is in how compounded BHRT is sometimes marketed. A common misconception, often amplified by clinicians with financial incentives tied to compounding relationships, is that bioidentical hormones are only available through compounding pharmacies. This is not true. As we'll discuss below, FDA-approved bioidentical hormone preparations are widely available and have robust clinical evidence behind them. Women who are told that the only way to access "true" BHRT is through a compounding pharmacy are often being given incomplete or misleading information.

A few other considerations worth knowing:

Saliva testing has limitations. Saliva hormone levels do not reliably reflect blood or tissue hormone levels and are not considered a valid basis for clinical dosing decisions by TMS or other major medical organizations. Serum testing is the standard.

Quality varies. Not all compounding pharmacies operate to the same standard. Working with one that validates its products and follows rigorous quality practices matters, and your clinician should be able to guide you toward reputable options if compounding is appropriate for your situation.

The "natural" framing

The word natural does significant work in how BHRT is marketed, and it's worth examining what it actually means in this context.

Bioidentical hormones are derived from plant sources, typically wild yam or soy, and are then chemically processed in a laboratory to produce hormones structurally identical to those naturally produced by the human body. The end product is a pharmaceutical compound. The plant origin is not what matters clinically. What matters is whether the hormone molecule is safe, effective, and consistently dosed.

FDA-approved bioidentical hormones like estradiol and micronized progesterone offer the structural identity that BHRT advocates emphasize while also having the safety data and manufacturing consistency of regulated medications. For most women, they represent the best of both frameworks.

Do bioidentical hormones have a safety advantage?

This is where the evidence is genuinely informative, and it's worth being clear: bioidentical hormones do have documented safety benefits compared to some synthetic formulations, though neither category should be demonized.

Progesterone vs synthetic progestins. Oral micronized progesterone (OMP) is not associated with an increased risk of blood clots, while some synthetic progestins carry a modestly elevated clot risk depending on the type used. To put that risk in perspective, the baseline clot risk for a healthy woman in her 50s not on hormones is approximately 1 in 1000. With progestins that do increase clot risk, that rises to roughly 2 to 3 in 1000, a real difference worth knowing about but a low absolute risk for most women. On breast cancer risk, the French E3N cohort study found no increased risk of breast cancer with oral micronized progesterone, a finding that distinguishes it from synthetic progestins, which have shown a small but measurable increase in risk. It is worth noting that synthetic progestins do a better job at controlling uterine bleeding and some can prevent pregnancy, which is clinically relevant for women in perimenopause who may still be ovulating. The right choice depends on the individual clinical picture.

Estradiol vs conjugated equine estrogen (CEE). Transdermal estradiol has a meaningful safety advantage when it comes to clot risk. Because it bypasses first-pass liver metabolism, it does not produce the prothrombotic changes in clotting factors that oral estrogen can. CEE, which is not available in a transdermal formulation, does produce a more prothrombotic profile even when given orally, and estradiol shows a more favorable profile by this measure as well. That said, some women do not tolerate estradiol well and do better on CEE. The absolute risk differences are modest, and CEE remains an appropriate option for many women. No formulation should be dismissed outright.

The takeaway is not that synthetic hormones are unsafe. For most women they are not. It is that bioidentical formulations have specific, documented advantages in certain areas of safety that are worth factoring into individualized treatment decisions.

What the evidence says about hormone therapy broadly

The history of hormone therapy has been shaped significantly by the Women's Health Initiative (WHI), a large study published in 2002 that reported increased risks of breast cancer, heart disease, stroke, and blood clots in women using combined hormone therapy. The study caused a dramatic drop in hormone therapy use that persisted for years.

Subsequent analysis has substantially revised that picture. The WHI studied a specific population (older postmenopausal women, average age 63) using a specific formulation (oral conjugated equine estrogen with synthetic progestin). Its findings do not apply equally to younger women, to women in early perimenopause or early postmenopause, or to the bioidentical hormone formulations and non-oral delivery methods that are now standard in modern menopause care.

The current position of TMS and most major menopause societies is that for healthy women under 60 or within 10 years of menopause onset, the benefits of hormone therapy generally outweigh the risks for the treatment of bothersome menopausal symptoms. This is a useful framework, but it is a guideline rather than a hard cutoff. For many women outside this window, hormone therapy can still be used safely after thorough individualized assessment and risk evaluation, particularly in the context of osteoporosis prevention, where the benefits of continued hormonal support may be substantial. The blanket fear that followed the WHI publication is not supported by the current evidence base, and neither is a rigid age-based approach that forecloses options for women who could genuinely benefit.

So which is right for you?

For most women, FDA-approved bioidentical hormone therapy, estradiol combined with micronized progesterone where a progestogen is needed, offers the most evidence-supported approach with well-characterized safety advantages. Compounded hormones remain a legitimate option for women with specific needs that standard formulations cannot meet, provided they are working with a reputable pharmacy and a clinician who understands the full picture.

What matters most is not which label a hormone product carries. It is whether the treatment is appropriate for your individual health history, your symptoms, and your goals, and whether it is being managed by a clinician who is up to date on the evidence, takes the time to understand your full picture, and is not guided by financial incentives in either direction.

How Glow Health can help

At Glow Health, we stay current with the evolving evidence on hormone therapy and provide individualized care that goes beyond the HRT vs BHRT debate. We help women understand their options clearly, without the marketing noise, so they can make informed decisions that are right for them.

If you have questions about hormone therapy or have been told that one approach is categorically safer or more natural than another, we'd welcome the conversation.

Keywords: HRT vs BHRT, bioidentical hormone therapy, bioidentical hormones menopause, compounded hormones, hormone replacement therapy menopause, is BHRT safe, bioidentical progesterone, estradiol menopause

This post is for informational purposes only and does not constitute medical advice. Please consult a qualified healthcare clinician for personalized guidance.